A Breakthrough in HFpEF: Usage and Outcomes of SGLT2 Inhibitors
City
Webinar
Type of event
virtual
Invitation
Dear Dr.
The Zurich Heart House would like to invite you to a special webinar on
A Breakthrough in HFpEF: Usage and Outcomes of SGLT2 Inhibitors
Date: Wednesday, November 10th, 2021, 17:00 – 18:30 CET
We are looking forward to meeting you during this webinar.
Thomas F. Lüscher, Zürich and London
Mattia Arrigo, Zürich
Otmar Pfister, Basel
Organized by
Programme
Chairs in ZHH Studio: Mattia Arrigo, Zürich, Otmar Pfister, Basel and Thomas F. Lüscher, Zürich and London
| 17:00 | Welcome and introduction | Thomas F. Lüscher, Zurich/London |
| 17:10 | What is HFpEF? The ESC Guideline definition | Theresa McDonagh, London |
| 17:25 | Imaging patients with HFpEF: What criteria count? | Jeroen J. Bax, Leiden |
| 17:40 | EMPEROR-Preserved: SGLT2 inhibition in HFpEF | Michael Böhm, Homburg |
| 17:55 | SGLT2 inhibition in clinical practice: Which HF patients? | Otmar Pfister, Basel |
| 18:10 | Panel discussion | Faculty |
This programme is supported by Boehringer Ingelheim.
The scientific programme has not been influenced in any way by its sponsor.
Accreditation
This webinar has been accredited with 2 SGK Credits.